Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (268)
  2. Journal Article (248)
  3. Review (27)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (583)
  2. Gastrointestinal Oncology Service (583)
  3. Solid Tumor Oncology Division (583)
  4. Center for Pancreatic Cancer Research (219)
  5. Epidemiology and Biostatistics (125)
  6. Surgery (104)

More Groups

People
  1. Eileen O'Reilly (160)
  2. James Harding (135)
  3. Marinela Capanu (67)
  4. William Jarnagin (67)
  5. Imane El Dika (55)
  6. Leonard Saltz (55)

More People

Years
  1. 2025 (28)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (167)
  2. Annals of Oncology (57)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (184)
  2. Oxford University Press (69)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (583)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Rimassa, L.; Cicin, I.; Blanc, J. F.; Klümpen, H. J.; Zagonel, V.; Tran, A.; Kim, S. C. H.; Lin, Z. Z.; Tam, V. C.; Hazra, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A. D.; Parnis, F.; Knox, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Do, R. K. G.; Hollywood, E.; Uhlitskykh, K.; Valentino, E.; Wan, P. J.; Hamilton, C. R.; Frick, J.; Feng, X.; Johnston, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Kelley, R. K.; Tan, B. R.; Iobst, E.; Boussayoud, C.; Muenkel, K. E.; Do, R. K. G.; Chou, J. F.; Capanu, M.; Ruiz, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Erinjeri, J. P.; Tan, B. R.; Reiss, K. A.; Mody, K.; Khalil, D.; Yarmohammadi, H.; Nadolski, G.; Giardina, J. D.; Capanu, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S)
    Meeting Abstract

    El Dika, I. H.; Capanu, M.; Chou, J. F.; Harding, J. J.; Hrabovsky, A. D.; Do, R. K. G.; Shia, J.; Germino, J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial
    Meeting Abstract

    Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Chen, Y. H.; Park, J. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study
    Meeting Abstract

    Abou-Alfa, G. K.; Chan, S. L.; Furuse, J.; Galle, P. R.; Kelley, R. K.; Qin, S.; Armstrong, J.; Darilay, A.; Vlahovic, G.; Negro, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8)
    Meeting Abstract

    Abou-Alfa, G. K.; Shi, Q.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Lammers, P. E.; Bekaii-Saab, T. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial
    Meeting Abstract

    Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Park, J. W.; Blanc, J. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save